JP6812542B2 - テトラヒドロピリジン誘導体および抗菌剤としてのその使用 - Google Patents
テトラヒドロピリジン誘導体および抗菌剤としてのその使用 Download PDFInfo
- Publication number
- JP6812542B2 JP6812542B2 JP2019516938A JP2019516938A JP6812542B2 JP 6812542 B2 JP6812542 B2 JP 6812542B2 JP 2019516938 A JP2019516938 A JP 2019516938A JP 2019516938 A JP2019516938 A JP 2019516938A JP 6812542 B2 JP6812542 B2 JP 6812542B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- methylsulfonyl
- dihydropyridine
- hydroxy
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003242 anti bacterial agent Substances 0.000 title description 16
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical class C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 title description 5
- -1 tetrahydropyridine compound Chemical class 0.000 claims description 158
- 150000001875 compounds Chemical class 0.000 claims description 149
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 141
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 98
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims description 74
- 239000002253 acid Substances 0.000 claims description 45
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 33
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 23
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 20
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 125000001072 heteroaryl group Chemical group 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 208000035143 Bacterial infection Diseases 0.000 claims description 14
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 14
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 14
- 241000894006 Bacteria Species 0.000 claims description 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 208000015181 infectious disease Diseases 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 9
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000001137 3-hydroxypropoxy group Chemical group [H]OC([H])([H])C([H])([H])C([H])([H])O* 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 5
- 125000001544 thienyl group Chemical group 0.000 claims description 5
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- YTEIHWVCQJZNEN-UHFFFAOYSA-N 3-pyridin-4-ylpyridine Chemical compound C1=CN=CC(C=2C=CN=CC=2)=C1 YTEIHWVCQJZNEN-UHFFFAOYSA-N 0.000 claims description 4
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 208000032376 Lung infection Diseases 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- 208000014912 Central Nervous System Infections Diseases 0.000 claims description 2
- 206010060803 Diabetic foot infection Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 206010062255 Soft tissue infection Diseases 0.000 claims description 2
- VCTNKKBDNYNBEX-UHFFFAOYSA-N [4-[4-[1-[4-(hydroxyamino)-3-methyl-3-methylsulfonyl-4-oxobutyl]-3,6-dihydro-2H-pyridin-4-yl]phenyl]phenyl]methanesulfonic acid Chemical compound ONC(C(CCN1CCC(=CC1)C1=CC=C(C=C1)C1=CC=C(C=C1)CS(=O)(=O)O)(S(=O)(=O)C)C)=O VCTNKKBDNYNBEX-UHFFFAOYSA-N 0.000 claims description 2
- 208000025222 central nervous system infectious disease Diseases 0.000 claims description 2
- 206010014665 endocarditis Diseases 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 208000019206 urinary tract infection Diseases 0.000 claims description 2
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 description 180
- 230000015572 biosynthetic process Effects 0.000 description 173
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 114
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 109
- 239000000203 mixture Substances 0.000 description 98
- 239000000243 solution Substances 0.000 description 80
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 74
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 69
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 66
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 63
- 238000004440 column chromatography Methods 0.000 description 56
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 51
- 238000000034 method Methods 0.000 description 47
- 239000012044 organic layer Substances 0.000 description 46
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 39
- 239000012267 brine Substances 0.000 description 36
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 36
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- 239000000543 intermediate Substances 0.000 description 26
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 12
- 229940088710 antibiotic agent Drugs 0.000 description 12
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 11
- UUIQMZJEGPQKFD-UHFFFAOYSA-N n-butyric acid methyl ester Natural products CCCC(=O)OC UUIQMZJEGPQKFD-UHFFFAOYSA-N 0.000 description 11
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 8
- 239000007821 HATU Substances 0.000 description 8
- 241000588697 Enterobacter cloacae Species 0.000 description 7
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 108090000204 Dipeptidase 1 Proteins 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 6
- 241000588747 Klebsiella pneumoniae Species 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 102000006635 beta-lactamase Human genes 0.000 description 6
- 150000007942 carboxylates Chemical class 0.000 description 6
- VLQFDTMNCJXVKM-UHFFFAOYSA-N methyl 4-bromo-2-methyl-2-methylsulfonylbutanoate Chemical compound BrCCC(C(=O)OC)(S(=O)(=O)C)C VLQFDTMNCJXVKM-UHFFFAOYSA-N 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- FBTNXKPMTVSCRR-UHFFFAOYSA-N n-methylsulfonylbutanamide Chemical compound CCCC(=O)NS(C)(=O)=O FBTNXKPMTVSCRR-UHFFFAOYSA-N 0.000 description 5
- BSIMZHVOQZIAOY-SCSAIBSYSA-N 1-carbapenem-3-carboxylic acid Chemical compound OC(=O)C1=CC[C@@H]2CC(=O)N12 BSIMZHVOQZIAOY-SCSAIBSYSA-N 0.000 description 4
- 241000588626 Acinetobacter baumannii Species 0.000 description 4
- 241000588914 Enterobacter Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- ZEOCVIVZDXOCOS-UHFFFAOYSA-N IC1=CC=C(C=C1)C=1CCN(CC1)CCC(C)(S(=O)(=O)C)C Chemical compound IC1=CC=C(C=C1)C=1CCN(CC1)CCC(C)(S(=O)(=O)C)C ZEOCVIVZDXOCOS-UHFFFAOYSA-N 0.000 description 4
- 241000588749 Klebsiella oxytoca Species 0.000 description 4
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 241000589516 Pseudomonas Species 0.000 description 4
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 4
- 239000012346 acetyl chloride Substances 0.000 description 4
- INRZEEFKABADJN-UHFFFAOYSA-N ethylsulfonyl butanoate Chemical compound C(CCC)(=O)OS(=O)(=O)CC INRZEEFKABADJN-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 208000027096 gram-negative bacterial infections Diseases 0.000 description 4
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 229930186147 Cephalosporin Natural products 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- NXLQMLJPTAHJSD-UHFFFAOYSA-N N1CC(C1)C#CC1=CC=C(C=C1)C=1CCN(CC1)CCC(C(=O)O)(S(=O)(=O)C)C Chemical compound N1CC(C1)C#CC1=CC=C(C=C1)C=1CCN(CC1)CCC(C(=O)O)(S(=O)(=O)C)C NXLQMLJPTAHJSD-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 3
- 108010003026 UDP-3-O-acyl-N-acetylglucosamine deacetylase Proteins 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000003781 beta lactamase inhibitor Substances 0.000 description 3
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 3
- 239000001273 butane Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 229940124587 cephalosporin Drugs 0.000 description 3
- 150000001780 cephalosporins Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 3
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 3
- OPAXKJALNDKTAD-UHFFFAOYSA-N o-(oxan-2-yl)hydroxylamine;hydrochloride Chemical compound Cl.NOC1CCCCO1 OPAXKJALNDKTAD-UHFFFAOYSA-N 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 description 3
- SQHSJJGGWYIFCD-UHFFFAOYSA-N (e)-1-diazonio-1-dimethoxyphosphorylprop-1-en-2-olate Chemical compound COP(=O)(OC)C(\[N+]#N)=C(\C)[O-] SQHSJJGGWYIFCD-UHFFFAOYSA-N 0.000 description 2
- QDGWHWNZEWWQMY-UHFFFAOYSA-N 2-methyl-2-methylsulfonyl-4-[4-(4-pyridin-4-ylphenyl)-3,6-dihydro-2H-pyridin-1-yl]butanoic acid Chemical compound CC(C(=O)O)(CCN1CCC(=CC1)C1=CC=C(C=C1)C1=CC=NC=C1)S(=O)(=O)C QDGWHWNZEWWQMY-UHFFFAOYSA-N 0.000 description 2
- LHTYOLUEPPFRBV-UHFFFAOYSA-N 2-methyl-2-methylsulfonylbutanoic acid Chemical compound CCC(C)(C(O)=O)S(C)(=O)=O LHTYOLUEPPFRBV-UHFFFAOYSA-N 0.000 description 2
- 125000004326 2H-pyran-2-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])(*)O1 0.000 description 2
- ZDLUCTBOMCTLNM-UHFFFAOYSA-N 4-(4-phenylphenyl)-1,2,3,6-tetrahydropyridine 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1CC(=CCN1)c1ccc(cc1)-c1ccccc1 ZDLUCTBOMCTLNM-UHFFFAOYSA-N 0.000 description 2
- QFXDCNKZPMMKMR-UHFFFAOYSA-N 4-[2-(1,2,3,6-tetrahydropyridin-4-yl)ethynyl]pyridine hydrochloride Chemical compound Cl.C1CC(=CCN1)C#Cc1ccncc1 QFXDCNKZPMMKMR-UHFFFAOYSA-N 0.000 description 2
- JQBGZIMTSFIAPS-UHFFFAOYSA-N 4-[4-(4-iodophenyl)-3,6-dihydro-2H-pyridin-1-yl]-2-methyl-2-methylsulfonylbutanoic acid Chemical compound IC1=CC=C(C=C1)C=1CCN(CC=1)CCC(C(=O)O)(S(=O)(=O)C)C JQBGZIMTSFIAPS-UHFFFAOYSA-N 0.000 description 2
- KHQAFOOAJHOTDD-UHFFFAOYSA-N 4-ethynyl-1-methylimidazole Chemical compound CN1C=NC(C#C)=C1 KHQAFOOAJHOTDD-UHFFFAOYSA-N 0.000 description 2
- 241000589291 Acinetobacter Species 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000589562 Brucella Species 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 241000588921 Enterobacteriaceae Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000605909 Fusobacterium Species 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000588915 Klebsiella aerogenes Species 0.000 description 2
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000607715 Serratia marcescens Species 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000607598 Vibrio Species 0.000 description 2
- 241000607734 Yersinia <bacteria> Species 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000007630 basic procedure Methods 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940092559 enterobacter aerogenes Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- YJDYQFYKYAYBMU-UHFFFAOYSA-N n-(oxan-2-yloxy)butanamide Chemical compound CCCC(=O)NOC1CCCCO1 YJDYQFYKYAYBMU-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- UENGYBYGCXKNRF-UHFFFAOYSA-N tert-butyl 3-ethynylazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(C#C)C1 UENGYBYGCXKNRF-UHFFFAOYSA-N 0.000 description 2
- CRSRUJYUXUFCRZ-UHFFFAOYSA-N tert-butyl 4-(2-pyridin-4-ylethynyl)-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound N1=CC=C(C=C1)C#CC=1CCN(CC=1)C(=O)OC(C)(C)C CRSRUJYUXUFCRZ-UHFFFAOYSA-N 0.000 description 2
- AQSDCHLORCHMAI-UHFFFAOYSA-N tert-butyl 4-(2-trimethylsilylethynyl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C#C[Si](C)(C)C)=CC1 AQSDCHLORCHMAI-UHFFFAOYSA-N 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- 150000003952 β-lactams Chemical class 0.000 description 2
- UIGXGNUMMVHJKX-UHFFFAOYSA-N (4-formylphenoxy)boronic acid Chemical compound OB(O)OC1=CC=C(C=O)C=C1 UIGXGNUMMVHJKX-UHFFFAOYSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 1
- OCODJNASCDFXSR-UHFFFAOYSA-N 1-bromo-2-fluoro-4-iodobenzene Chemical compound FC1=CC(I)=CC=C1Br OCODJNASCDFXSR-UHFFFAOYSA-N 0.000 description 1
- UCCUXODGPMAHRL-UHFFFAOYSA-N 1-bromo-4-iodobenzene Chemical compound BrC1=CC=C(I)C=C1 UCCUXODGPMAHRL-UHFFFAOYSA-N 0.000 description 1
- PKJBWOWQJHHAHG-UHFFFAOYSA-N 1-bromo-4-phenylbenzene Chemical group C1=CC(Br)=CC=C1C1=CC=CC=C1 PKJBWOWQJHHAHG-UHFFFAOYSA-N 0.000 description 1
- CQZXDIHVSPZIGF-UHFFFAOYSA-N 1-methylimidazole-4-carbaldehyde Chemical compound CN1C=NC(C=O)=C1 CQZXDIHVSPZIGF-UHFFFAOYSA-N 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- ZHXUWDPHUQHFOV-UHFFFAOYSA-N 2,5-dibromopyridine Chemical compound BrC1=CC=C(Br)N=C1 ZHXUWDPHUQHFOV-UHFFFAOYSA-N 0.000 description 1
- LWISLHRIEATKTM-UHFFFAOYSA-N 2-Ethynylthiophene Chemical compound C#CC1=CC=CS1 LWISLHRIEATKTM-UHFFFAOYSA-N 0.000 description 1
- BXSHKKQMMWFEFK-UHFFFAOYSA-N 2-methyl-2-methylsulfonyl-3-[4-(4-phenylphenyl)-3,6-dihydro-2H-pyridin-1-yl]propanoic acid Chemical compound C1(=CC=C(C=C1)C=1CCN(CC=1)CC(C(=O)O)(S(=O)(=O)C)C)C1=CC=CC=C1 BXSHKKQMMWFEFK-UHFFFAOYSA-N 0.000 description 1
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- QZCKSWWFLXTZOX-UHFFFAOYSA-N 3-methylsulfonylpentane Chemical compound CCC(CC)S(C)(=O)=O QZCKSWWFLXTZOX-UHFFFAOYSA-N 0.000 description 1
- VQBBQSDNNIYUJT-UHFFFAOYSA-N 4-(4-iodophenyl)-1,2,3,6-tetrahydropyridine hydrochloride Chemical compound Cl.Ic1ccc(cc1)C1=CCNCC1 VQBBQSDNNIYUJT-UHFFFAOYSA-N 0.000 description 1
- FTIZUXGKTNJZEG-UHFFFAOYSA-N 4-bromo-1-iodo-2-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC(Br)=CC=C1I FTIZUXGKTNJZEG-UHFFFAOYSA-N 0.000 description 1
- GHTUADBHTFHMNI-UHFFFAOYSA-N 4-bromo-1-iodo-2-methylbenzene Chemical compound CC1=CC(Br)=CC=C1I GHTUADBHTFHMNI-UHFFFAOYSA-N 0.000 description 1
- XRMZKCQCINEBEI-UHFFFAOYSA-N 4-bromo-2-fluoro-1-iodobenzene Chemical compound FC1=CC(Br)=CC=C1I XRMZKCQCINEBEI-UHFFFAOYSA-N 0.000 description 1
- UPCARQPLANFGQJ-UHFFFAOYSA-N 4-bromo-2-fluorobenzaldehyde Chemical compound FC1=CC(Br)=CC=C1C=O UPCARQPLANFGQJ-UHFFFAOYSA-N 0.000 description 1
- ZRYZBQLXDKPBDU-UHFFFAOYSA-N 4-bromobenzaldehyde Chemical compound BrC1=CC=C(C=O)C=C1 ZRYZBQLXDKPBDU-UHFFFAOYSA-N 0.000 description 1
- ZWMAYLMVFSCMMS-UHFFFAOYSA-N 4-ethynyl-n,n-dimethylaniline Chemical compound CN(C)C1=CC=C(C#C)C=C1 ZWMAYLMVFSCMMS-UHFFFAOYSA-N 0.000 description 1
- RTLUPHDWSUGAOS-UHFFFAOYSA-N 4-iodopyridine Chemical compound IC1=CC=NC=C1 RTLUPHDWSUGAOS-UHFFFAOYSA-N 0.000 description 1
- NLWAKVGODLJALJ-UHFFFAOYSA-N 5-bromo-1,3-difluoro-2-iodobenzene Chemical compound FC1=CC(Br)=CC(F)=C1I NLWAKVGODLJALJ-UHFFFAOYSA-N 0.000 description 1
- 241000590020 Achromobacter Species 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241001148536 Bacteroides sp. Species 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 241000589513 Burkholderia cepacia Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- HTSNDVCLSJQDCE-UHFFFAOYSA-N C(C)(=O)N1CC(C1)C#CC1=CC=C(C=C1)C=1CCN(CC1)CCC(C)(S(=O)(=O)C)C Chemical compound C(C)(=O)N1CC(C1)C#CC1=CC=C(C=C1)C=1CCN(CC1)CCC(C)(S(=O)(=O)C)C HTSNDVCLSJQDCE-UHFFFAOYSA-N 0.000 description 1
- IWSPPHWTEWSZHD-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CC=C1C#C)=O Chemical compound CC(C)(C)OC(N(CC1)CC=C1C#C)=O IWSPPHWTEWSZHD-UHFFFAOYSA-N 0.000 description 1
- SPXBLLUDBVCKJS-UHFFFAOYSA-N CC(C)(CCN1CCC(=CC1)C1=CC=C(C=C1)C#CC1CN(C1)C)S(=O)(=O)C Chemical compound CC(C)(CCN1CCC(=CC1)C1=CC=C(C=C1)C#CC1CN(C1)C)S(=O)(=O)C SPXBLLUDBVCKJS-UHFFFAOYSA-N 0.000 description 1
- OLKDLHWBGRVHTP-UHFFFAOYSA-N CC(CCN(CC1)CC=C1C1(C)C=CC(C#CCCCO)=CC1)(C(OC)=O)[S](C)(C)(=O)=O Chemical compound CC(CCN(CC1)CC=C1C1(C)C=CC(C#CCCCO)=CC1)(C(OC)=O)[S](C)(C)(=O)=O OLKDLHWBGRVHTP-UHFFFAOYSA-N 0.000 description 1
- GFFZZQACKGAUBM-UHFFFAOYSA-N CC(CCNCC#C)(C(OC)=O)S(C)(=O)=O Chemical compound CC(CCNCC#C)(C(OC)=O)S(C)(=O)=O GFFZZQACKGAUBM-UHFFFAOYSA-N 0.000 description 1
- YQOQHXFWBVXMEF-UHFFFAOYSA-O CC(CC[NH+](CC1)CC=C1c(cc1)cc(F)c1C#CCN(C)C)(C(NOC1OCCCC1)=O)S(C)(=O)=O Chemical compound CC(CC[NH+](CC1)CC=C1c(cc1)cc(F)c1C#CCN(C)C)(C(NOC1OCCCC1)=O)S(C)(=O)=O YQOQHXFWBVXMEF-UHFFFAOYSA-O 0.000 description 1
- ADUGLPOVBGHYCE-UHFFFAOYSA-N CC(CN(CC1)CC=C1C(CC1)=CC=C1C1=CC=CCC1)(C(OC)=O)/S=[O]/C Chemical compound CC(CN(CC1)CC=C1C(CC1)=CC=C1C1=CC=CCC1)(C(OC)=O)/S=[O]/C ADUGLPOVBGHYCE-UHFFFAOYSA-N 0.000 description 1
- MLTUZNAHBBRPLC-UHFFFAOYSA-N CC(CN(CC1)CC=C1C(CC=C1)=CC=C1c1ccccc1)(C(NOC1OCCCC1)=O)/S=[O]/C Chemical compound CC(CN(CC1)CC=C1C(CC=C1)=CC=C1c1ccccc1)(C(NOC1OCCCC1)=O)/S=[O]/C MLTUZNAHBBRPLC-UHFFFAOYSA-N 0.000 description 1
- PMOSCJABMDXVLG-UHFFFAOYSA-N CC(CN(CC1)CC=C1c(cc1)ccc1-c1ccccc1)(C(O)=O)/S=[O]/C Chemical compound CC(CN(CC1)CC=C1c(cc1)ccc1-c1ccccc1)(C(O)=O)/S=[O]/C PMOSCJABMDXVLG-UHFFFAOYSA-N 0.000 description 1
- LHIYKPZEDXOGDA-UHFFFAOYSA-N CC(CN(CC1)CC=C1c(cc1)ccc1-c1ccccc1)(C(O)=O)S(=O)=O Chemical compound CC(CN(CC1)CC=C1c(cc1)ccc1-c1ccccc1)(C(O)=O)S(=O)=O LHIYKPZEDXOGDA-UHFFFAOYSA-N 0.000 description 1
- BZZBFWGAYGGFTO-PXYINDEMSA-N CCC#CC(C=CC12)=C[C@H]1C=C2N(C)I Chemical compound CCC#CC(C=CC12)=C[C@H]1C=C2N(C)I BZZBFWGAYGGFTO-PXYINDEMSA-N 0.000 description 1
- 0 CCCCNC*C(C)([C@]1(N)OC1)S(C)(=O)=O Chemical compound CCCCNC*C(C)([C@]1(N)OC1)S(C)(=O)=O 0.000 description 1
- VGOYWCPGKWOLJZ-JGVFFNPUSA-N CC[C@](C)(CO)N(C)[C@H](C)O Chemical compound CC[C@](C)(CO)N(C)[C@H](C)O VGOYWCPGKWOLJZ-JGVFFNPUSA-N 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- HVVNJUAVDAZWCB-RXMQYKEDSA-N D-prolinol Chemical compound OC[C@H]1CCCN1 HVVNJUAVDAZWCB-RXMQYKEDSA-N 0.000 description 1
- 108010013198 Daptomycin Proteins 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 241001293415 Mannheimia Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 241000588772 Morganella morganii Species 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 description 1
- 101150026476 PAO1 gene Proteins 0.000 description 1
- REEDQGDXEGRSSH-UHFFFAOYSA-N PC1OCCCC1 Chemical compound PC1OCCCC1 REEDQGDXEGRSSH-UHFFFAOYSA-N 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 241000605894 Porphyromonas Species 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000588768 Providencia Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 241000122971 Stenotrophomonas Species 0.000 description 1
- 241000122973 Stenotrophomonas maltophilia Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 108010053950 Teicoplanin Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 208000034784 Tularaemia Diseases 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000002814 agar dilution Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- UCKZMPLVLCKKMO-LHLIQPBNSA-N cephamycin Chemical compound S1CC(C)=C(C(O)=O)N2C(=O)[C@@H](C)[C@]21OC UCKZMPLVLCKKMO-LHLIQPBNSA-N 0.000 description 1
- JQXXHWHPUNPDRT-YOPQJBRCSA-N chembl1332716 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CCN(C)CC1 JQXXHWHPUNPDRT-YOPQJBRCSA-N 0.000 description 1
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 1
- 229960005484 daptomycin Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000000883 ear external Anatomy 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940118764 francisella tularensis Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000000752 ionisation method Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-M isobutyrate Chemical compound CC(C)C([O-])=O KQNPFQTWMSNSAP-UHFFFAOYSA-M 0.000 description 1
- 125000005921 isopentoxy group Chemical group 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 102000020235 metallo-beta-lactamase Human genes 0.000 description 1
- 108060004734 metallo-beta-lactamase Proteins 0.000 description 1
- FBBDOOHMGLLEGJ-UHFFFAOYSA-N methane;hydrochloride Chemical compound C.Cl FBBDOOHMGLLEGJ-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- SKTCDJAMAYNROS-UHFFFAOYSA-N methoxycyclopentane Chemical compound COC1CCCC1 SKTCDJAMAYNROS-UHFFFAOYSA-N 0.000 description 1
- JLEJCNOTNLZCHQ-UHFFFAOYSA-N methyl 2-chloropropanoate Chemical compound COC(=O)C(C)Cl JLEJCNOTNLZCHQ-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940076266 morganella morganii Drugs 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- HEDOODBJFVUQMS-UHFFFAOYSA-N n-[2-(5-methoxy-1h-indol-3-yl)ethyl]-n-methylpropan-2-amine Chemical group COC1=CC=C2NC=C(CCN(C)C(C)C)C2=C1 HEDOODBJFVUQMS-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 229960002950 novobiocin Drugs 0.000 description 1
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- LYPGDCWPTHTUDO-UHFFFAOYSA-M sodium;methanesulfinate Chemical compound [Na+].CS([O-])=O LYPGDCWPTHTUDO-UHFFFAOYSA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229960001608 teicoplanin Drugs 0.000 description 1
- GVQMAQNQGVDWQP-UHFFFAOYSA-N tert-butyl 4-(3-fluoro-4-formylphenyl)-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound FC=1C=C(C=CC=1C=O)C=1CCN(CC=1)C(=O)OC(C)(C)C GVQMAQNQGVDWQP-UHFFFAOYSA-N 0.000 description 1
- GJXAQQQCWCVUDI-UHFFFAOYSA-N tert-butyl 4-[4-(2,2-dibromoethenyl)-3-fluorophenyl]-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound BrC(=CC1=C(C=C(C=C1)C=1CCN(CC=1)C(=O)OC(C)(C)C)F)Br GJXAQQQCWCVUDI-UHFFFAOYSA-N 0.000 description 1
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 1
- QUERMGFVJPRMJL-UHFFFAOYSA-N tert-butyl azetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC1 QUERMGFVJPRMJL-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229940072172 tetracycline antibiotic Drugs 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical compound C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
ル、アリールまたはヘテロアリールであり、
ARB、ハロゲン、ニトロ、シアノ、−NRARB、−OH、−ORC、−S(=O)2−C1〜C6アルキルまたは−S(=O)2−NRARBで置換されていてもよく;
ラニル、イミダゾリジニル、ピロリジニル、ピペリジニル、ピペラジニル、オキサゾリジニル、チアゾリジニル、ピラゾリジニル、モルホリニル、チオ−モルホリニル、オキサジニルまたはテトラヒドロピリジニルが挙げられるが、これらに限定はされない。
タンアミド;
イル)ブタンアミド;
ルスルホニル)ブタンアミド;
pneumoniae)、(基質特異性拡張型βラクタマーゼ(以後、「ESBL」)をコードする肺炎桿菌を含む)、在郷軍人病菌(Legionella pneumophila)、カタル球菌(Moraxella catarrhalis)(βラクタマーゼ陽性および陰性)、モルガン菌(Morganella morganii)、淋菌(Neisseria gonorrhoeae)、髄膜炎菌(Neisseria meningitides)、プロテウス・ブルガリス(Proteus vulgaris)、ポルフィロモナス属菌種(Porphyromonas spp.)、プレボテラ属菌種(Prevotella spp.)、現在利用可能なセファロスポリン系抗生物質、セファマイシン系抗生物質、カルバペネム系抗生物質、およびβラクタム/βラクタマーゼ阻害剤配合剤に対する耐性を与えるESBL KPC、CTX−M、メタロ−β−ラクタマーゼ、およびAmpC型β−ラクタマーゼを発現する腸内細菌科のメンバー、ヘモリチカ菌(Mannheimia haemolyticus)、パスツレラ属菌種(Pasteurella spp.)、プロテウス・ミラビリス(Proteus mirabilis)、プロビデンシア属菌種(Providencia spp.)、緑膿菌(Pseudomonas aeruginosa)(セフタジジム耐性、セフピロム耐性およびセフェピム(cefepime)耐性緑膿菌、カルバペネム耐性緑膿菌またはキノロン耐性緑膿菌を含む)、シュードモナス属菌種(Pseudomonas spp.)、サルモネラ属菌種(Salmonella spp.)、赤痢菌属菌種(Shigella spp.)、霊菌(Serratia marcescenes)、トレポネーマ属菌種(Treponema spp.)、セパシア菌(Burkholderia cepacia)、ビブリオ属菌種(Vibrio spp.)、エルシニア属菌種(Yersinia spp.)、およびステノトロフォモナス・マルトフィリア(Stenotrophomonas maltophilia)。
、KPS、CTX−M、メタロ−β−ラクタマーゼ、およびAmpC型β−ラクタマーゼを発現する腸内細菌科(Enterobacteriaceae)およびシュードモナス属(Pseudomonas)のメンバー。
に対するグラム陰性菌の外膜の透過性を向上させることができる。本開示による式Iの化合物またはその立体異性体は、別の抗菌剤と組み合わせて使用すると、使用量の減少または治療期間の短縮による薬物の副作用の低減、院内滞在時間を短縮するより迅速な感染症治癒、制御される病原体の範囲の増加、および抗生物質耐性の発生率の減少など、いくつかのさらなる利点が得られる場合がある。本開示による式Iの化合物と組み合わせて使用するための抗菌剤は、以下からなる群から選択される:ペニシリン系抗生物質(アンピシリン、ピペラシリン、ペニシリンG、アモキシシリン、またはテトラシリン(tetracillin)など)、セファロスポリン系抗生物質(セフトリアキソン、セフタジジム、セフェピム、セフォタキシムなど)、カルバペネム系抗生物質(イミペネム、またはメロペネムなど)、モノバクタム抗生物質(アズトレオナムなど)、フルオロキノロン系抗生物質(シプロフロキサシン、モキシフロキサシンまたはレボフロキサシンなど)、マクロライド系抗生物質(エリスロマイシンまたはアジスロマイシンなど)、アミノグリコシド抗生物質(アミカシン、ゲンタマイシンまたはトブラマイシンなど)、糖ペプチド抗生物質(バンコマイシンまたはテイコプラニンなど)、テトラサイクリン系抗生物質(テトラサイクリンなど)、およびリネゾリド、クリンダマイシン、テラバンシン、ダプトマイシン、ノボビオシン、リファンピシンおよびポリミキシン。
本開示による、治療有効量の式Iで表される化合物、その立体異性体またはその薬剤的に許容できる塩を投与することを含む、前記方法を提供する。
水溶液でクエンチし、酢酸エチルおよび水で抽出した。その有機層をブラインで洗浄し、無水MgSO4で乾燥し、減圧下で濃縮した。残渣をカラムクロマトグラフィーで精製することにより、表題化合物(225mg、43%)を調製した。
)−3,6−ジヒドロピリジン−1(2H)−イル)−2−メチル−2−(メチルスルホニル)ブタン酸メチル(2g、1当量)の溶液に、2N LiOH(12.6mL、3当量)溶液を加え、室温で2時間撹拌した。溶媒を減圧下で除去し、残渣を水(10ml)で希釈し、pHを4.0に調整した。水を真空中で濃縮し、残渣をカラムクロマトグラフィーにかけることにより、表題化合物(1.76g、91%)を調製した。
(s, 3H).
6.17 (s, 1H), 4.85-4.81 (m, 1H), 3.31-3.04 (m, 5H), 2.60-2.59 (m, 2H), 2.47-2.39 (m, 6H), 1.85-1.62 (m, 2H), 1.47-1.41 (s, 7H).
J=9Hz, 2H), 6.65 (d, J=8.4Hz, 2H), 6.08 (s, 1H), 3.87 (s, 3H), 3.24-3.22 (m, 1H), 3.07-3.05 (m, 1H), 3.04 (s, 3H), 2.98 (s, 6H), 2.82-2.76 (m, 1H), 2.67-2.56 (m, 4H), 2.62-2.58 (m, 2H), 2.03-2.00 (m, 1H), 1.63 (s, 3H).
1H), 2.87-2.84 (m, 1H), 2.71-2.67 (m, 1H), 2.20-2.19 (m, 1H), 1.93-1.72 (m, 4H).
3H).
33-7.28 (m, 2H), 6.19 (s, 1H), 4.52 (bs, 1H), 3.54-3.50 (m, 2H), 3.17-3.15 (m, 2H), 3.06 (s, 3H), 2.64-2.54 (m, 2H), 2.48-2.38 (m, 4H), 1.90-1.84 (m, 2H), 1.69-1.57 (m, 4H), 1.46 (s, 3H).
(m, 2H), 1.44 (s, 3H).
を加えた。その混合物を12時間還流させ、室温に冷却し、溶媒を減圧下で濃縮した。残渣をカラムクロマトグラフィーで精製することにより、表題化合物(80mg、46%)を調製した。
4.49 (s, 2H), 3.80-3.70 (m, 4H), 3.48-3.30 (m, 2H), 3.07-3.02 (m, 5H), 2.68-2.56 (m, 4H), 1.70-1.64 (m, 4H).
(0.19ml、2当量)を加えた。その混合物を室温で2時間撹拌した。ナトリウムメトキシド(MeOH中25%溶液、1.06g、4当量)を加え、60℃で3時間撹拌した。その混合物を室温に冷却し、ジクロロメタンおよび水で抽出した。その有機層をブラインで洗浄し、無水MgSO4で乾燥し、減圧下で濃縮した。残渣をカラムクロマトグラフィーで精製することにより、表題化合物(250mg、48%)を調製した。
(m, 3H), 1.78-1.68 (m, 3H), 1.64-1.52 (m, 4H).
した。
(m, 2H), 3.05 (s, 3H), 2.78 (s, 3H), 2.72-2.62 (m, 6H), 2.58-2.48 (m, 2H), 1.72-1.62 (m, 4H).
ホニル)−4−オキソブチル)−1,2,3,6−テトラヒドロピリジン−4−イル)フェニル)ペンタ−4−イン−1−イルカルバミン酸の合成
(m, 5H), 1.78-1.65 (m, 6H), 1.63 (s, 3H).
2H), 3.04 (s, 3H), 2.6-2.58 (m, 2H), 2.43-2.39 (m, 4H), 1.47 (s, 3H), 1.41-1.38
(m, 4H).
4.36 (s, 2H), 3.72-3.70 (m, 2H), 3.27-3.23 (m, 2H), 2.78 (s, 6H), 2.68-2.64 (m,
2H).
1H), 3.66 (s, 3H), 3.54 (s, 2H), 3.23-3.18 (m, 1H), 3.04 (s, 3H), 3.03-3.00 (m,
1H), 2.79-2.75 (1H), 2.67-2.60 (m, 2H), 2.58-2.54 (m, 2H), 2.46-2.42 (m, 2H), 2.36 (s, 6H), 2.00-1.97 (m, 1H), 1.62 (s, 3H).
)−2−メチル−2−(メチルスルホニル)−N−((テトラヒドロ−2H−ピラン−2−イル)オキシ)ブタンアミド(160mg、1当量)の溶液に、MeOH中HCl溶液(1.25N、0.72ml、3当量)を加え、その混合物を室温で2時間撹拌した。溶媒を減圧下で除去した。残渣を水(6ml)で希釈し、pHを7.0に調整した。水を濃縮し、得られた残渣をカラムクロマトグラフィーで精製することにより、表題化合物(89mg、57%)を調製した。
2H), 7.28-7.26 (m, 1H), 7.01-6.99 (m, 1H), 6.12 (s, 1H), 4.92-4.90 (m, 1H), 3.43-3.29 (m, 4H), 3.11 (s, 3H), 2.90-2.83 (m, 4H), 2.72-2.65 (m, 4H), 1.80-1.57 (m, 7H), 1.52-1.45 (s, 2 H).
た。
0当量)を加えた。その混合物を室温で3時間撹拌した。その後、溶媒を減圧下で濃縮することにより、表題化合物(4.2g、89%)を調製した。
3.76-3.74 (m, 2H), 3.66 (s, 3H), 3.46-3.45 (m, 1H), 3.22-3.19 (m, 3H), 3.02-2.99 (m, 4H), 2.78-2.76 (m, 1H), 2.65-2.53 (m, 4H), 2.47-2.46 (m, 2H), 2.38 (s, 3H), 1.97-1.96 (m, 1H), 1.62 (s, 3H).
2H), 3.15-3.14 (m, 2H), 3.04 (s, 3H), 2.62-2.56 (m, 2H), 2.49-2.43 (m, 4H), 2.32-2.30 (m, 1H), 1.74 (s, 3H), 1.44 (s, 3H).
7.16-7.14 (m, 1H), 6.24 (bs, 1H), 4.14-4.10 (m, 2H), 3.66-3.64 (m, 2H), 2.54-2.50 (m, 2H), 1.49 (s, 9H).
した。その有機層をブラインで洗浄し、無水MgSO4で乾燥し、減圧下で濃縮した。残渣をカラムクロマトグラフィーで精製することにより、表題化合物(4.13g、91%)を調製した。
で希釈し、pHを4.0に調整した。析出した固体を濾別して表題化合物(119mg、53%)を調製し、それをさらなる精製なしで次の工程に用いた。
2H), 6.09 (bs, 1H), 4.09-4.06 (m, 2H), 3.66- 3.61 (m, 2H), 2.55-2.49 (m, 2H), 1.49 (s, 9H).
ン酸tert−ブチルの合成
2.28-2.18 (m, 2H), 1.45 (s, 9H), 0.17 (s, 9H).
をカラムクロマトグラフィーで精製することにより、表題化合物(2.38g、97%)を調製した。
2.88 (s, 1H), 2.28-2.18 (m, 2H), 1.45 (s, 9H).
4.08-4.00 (m, 2H), 3.56-3.50 (m, 2H), 2.48-2.40 (m, 2H), 1.47 (s, 9H).
3.90-3.88 (m, 2H), 3.43-3.41 (m, 2H), 2.68-2.66 (m, 2H).
ニル)ブタン酸メチル(中間体1)(940mg、2当量)を加えた。その混合物を60℃で12時間撹拌し、室温に冷却し、酢酸エチルおよび水で抽出した。その有機層をブラインで洗浄し、無水MgSO4で乾燥し、減圧下で濃縮した。残渣をカラムクロマトグラフィーで精製することにより、表題化合物(85mg、13%)を調製した。
3.74 (s, 3H), 3.18-3.14 (m, 1H), 3.03 (s, 3H), 2.98-2.94 (m, 1H), 2.72-2.46 (m,
4H), 2.32-2.28 (m, 2H), 1.88-1.82 (m, 1H), 1.61 (s, 3H), 1.29-1.24 (m, 1H).
3.48-3.44 (m, 2H), 2.47-2.44 (m, 2H), 2.22-2.20 (m, 2H), 1.82-1.76 (m, 2H), 1.45 (s, 9H).
3.33-3.29 (m, 2H), 2.48-2.46 (m, 2H), 2.44-2.42 (m, 2H), 1.75-1.70 (m, 2H).
J=5.4Hz, 1H), 3.43-3.40 (m, 2H), 3.02 (s, 3H), 2.93-2.99 (m, 2H), 2.52-2.50 (m,
1H), 2.44-2.36 (m, 5H), 2.27-2.24 (m, 1H), 2.16-2.07 (m, 2H), 1.77-1.73 (m, 1H), 1.61-1.56 (m, 2H), 1.41 (s, 3H).
7.63-7.60 (m, 2H), 7.49-7.45 (m, 2H), 6.08 (s, 1H), 3.87 (s, 3H), 3.79-76 (m, 2H), 3.66-3.56 (m, 2H), 3.42-3.26 (m, 2H), 3.13 (s, 3H), 2.92-2.72 (m, 4H), 1.74 (s, 3H).
2H), 6.11-6.10 (m, 1H), 3.74-3.72 (m, 4H), 3.69 (s, 3H), 3.55 (s, 2H), 3.28-3.24 (m, 1H), 3.10-3.02 (m, 1H), 3.05 (s, 3H), 2.86-2.78 (m, 1H), 2.68-2.58 (m, 4H), 2.56-2.46 (m, 6H), 2.06-1.98 (m, 1H), 1.64 (s, 3H).
1H), 4.33(s, 2H), 3.67,(s, 3H), 3.45(s, 3H), 3.25(m, 1H), 3.07(m, 1H), 3.03(s, 3H), 2.81(m, 1H) 2.63-2.57(m, 3H), 2.57(m, 2H), 1.62(s, 3H).
7.08-7.05 (m, 1H), 6.15 (s, 1H), 3.76 (s, 2H), 3.25 (s, 2H), 2.65 (s, 2H).
(s, 2H), 3.18 (s, 3H), 3.05 (d, 1H, J=13.8 Hz), 2.81 (t, 2H, J=6.0Hz), 2.58-2.46 (m, 2H), 1.69(s, 3H).
2H), 3.61-3.49 (m, 4H), 3.15 (s, 3H), 2.47-2.40 (m, 2H), 1.48 (s, 3H).
Claims (8)
- 下記式Iで表されるテトラヒドロピリジン化合物、その立体異性体、またはその薬剤的に許容できる塩であって、
(式I)
式中、
nは1または2であり;
R1はC1〜C6アルキルであり;
R2 はC1〜C6アルキルであり;
R3は水素であり;
Lはアリール、ヘテロアリールであるかまたは存在せず、ここで、アリールまたはヘテロアリールの少なくとも1つのHはハロゲン、C1〜C6アルキルまたはC1〜C6ハロアルキルで置換されていてもよく;
DはC≡Cであるかまたは存在せず;
EはC≡Cであるかまたは存在せず(ここで、L、D及びEは同時には不存在にならない);
GはC1〜C6アルキル、C3〜C7シクロアルキル、4〜6員ヘテロシクロアルキル、アリールまたはヘテロアリールであり、
ここで、C1〜C6アルキルの少なくとも1つのHはハロゲン、−NRARB、−OHまたは−ORCで置換されていてもよく、
4〜6員ヘテロシクロアルキルの少なくとも1つのHはC1〜C6アルキル、−(C=O)−C1〜C6アルキルまたは−S(=O)2−C1〜C6アルキルで置換されていてもよく、
アリールまたはヘテロアリールの少なくとも1つのHはC1〜C6アルキル、C1〜C6ヒドロキシアルキル、C1〜C6アルキル−NRARB、ハロゲン、ニトロ、シアノ、−NRARB、−OH、−ORC、−S(=O)2−C1〜C6アルキルまたは−S(=O)2−NRAR B で置換されていてもよく;
RAおよびRBはそれぞれ独立して水素またはC1〜C6アルキルであるか、あるいは、RAおよびRBは一緒に結合して4〜6員環を形成していてもよく、ここで前記4〜6員環はO原子を有していてもよく、前記4〜6員環の少なくとも1つのHはC1〜C6ヒドロキシアルキルで置換されていてもよく;
RCはC1〜C6アルキル、C1〜C6ヒドロキシアルキル、−(C=O)−NRDREまたは−S(=O)2−C1〜C6アルキルであり;且つ、
RDおよびREはそれぞれ独立して水素である、
式Iで表されるテトラヒドロピリジン化合物、その立体異性体、またはその薬剤的に許容できる塩。 - nは1または2であり;
R1はC1〜C6アルキルであり;
R2はC1〜C6アルキルであり;
R3は水素であり;
Lはフェニル、ピリジニルであるかまたは存在せず、ここで、フェニルまたはピリジニルの少なくとも1つのHはハロゲン、C1〜C6アルキルまたはC1〜C6ハロアルキルで置換されていてもよく;
DはC≡Cであるかまたは存在せず;
EはC≡Cであるかまたは存在せず;
GはC1〜C6アルキル、C3〜C6シクロアルキル、4〜6員ヘテロシクロアルキル、フェニル、ピリジニル、フラニル、チオフェニルまたはイミダゾリルであり、
ここで、C1〜C6アルキルの少なくとも1つのHはハロゲン、−NRARB、−OHまたは−ORCで置換されていてもよく、
4〜6員ヘテロシクロアルキルの少なくとも1つのHはC1〜C6アルキル、−(C=O)−C1〜C6アルキルまたは−S(=O)2−C1〜C6アルキルで置換されていてもよく、
フェニル、ピリジニル、フラニル、チオフェニルまたはイミダゾリルの少なくとも1つのHはC1〜C6アルキル、C1〜C6ヒドロキシアルキル、C1〜C6アルキル−NRARB、ハロゲン、ニトロ、シアノ、−NRARB、−OH、−ORC、−S(=O)2−C1〜C6アルキルまたは−S(=O)2−NRARBで置換されていてもよく;
RAおよびRBはそれぞれ独立して水素またはC1〜C6アルキルであるか、あるいは、RAおよびRBは一緒に結合して4〜6員の環を形成していてもよく、ここで、前記4〜6員環はO原子を有していてもよく、前記4〜6員環の少なくとも1つのHはC1〜C6ヒドロキシアルキルで置換されていてもよく;
RCはC1〜C6アルキル、C1〜C6ヒドロキシアルキル、−(C=O)−NRDREまたは−S(=O)2−C1〜C6アルキルであり;且つ、
RDおよびREはそれぞれ独立して水素である、
請求項1に記載のテトラヒドロピリジン化合物、その立体異性体、またはその薬剤的に許容できる塩。 - 以下に記載の化合物からなる群から選択される、請求項2に記載のテトラヒドロピリジン化合物、その立体異性体またはその薬剤的に許容できる塩:
1)4−(4−(4−((4−(ジメチルアミノ)フェニル)エチニル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;
2)N−ヒドロキシ−2−メチル−2−(メチルスルホニル)−4−(4−(4−(フ
ェニルエチニル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)ブタンアミド;
3)N−ヒドロキシ−4−(4−(4−((4−メトキシフェニル)エチニル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−2−メチル−2−(メチルスルホニル)ブタンアミド;
4)4−(4−(4−(シクロプロピルエチニル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;
5)N−ヒドロキシ−4−(4−(4−(4−ヒドロキシブト−1−イン−1−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−2−メチル−2−(メチルスルホニル)ブタンアミド;
6)4−(4−(4−(ヘキサ−1−イン−1−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;
7)4−(4−(4−(3−(ジメチルアミノ)プロプ−1−イン−1−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;
8)N−ヒドロキシ−4−(4−(4−(3−ヒドロキシブト−1−イン−1−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−2−メチル−2−(メチルスルホニル)ブタンアミド;
9)4−(4−(4−(シクロペンチルエチニル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;
10)4−(4−(4−(シクロヘキシルエチニル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;
11)N−ヒドロキシ−2−メチル−2−(メチルスルホニル)−4−(4−(4−(ペンタ−1−イン−1−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)ブタンアミド;
13)N−ヒドロキシ−2−メチル−4−(4−(4−(4−メチルペンタ−1−イン−1−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−2−(メチルスルホニル)ブタンアミド;
14)4−(4−(4−(5−クロロペンタ−1−イン−1−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;
15)N−ヒドロキシ−2−メチル−2−(メチルスルホニル)−4−(4−(4−(3−(ピロリジン−1−イル)プロプ−1−イン−1−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)ブタンアミド;
16)4−(4−(4−(3−(ジエチルアミノ)プロプ−1−イン−1−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;
17)N−ヒドロキシ−4−(4−(4−(3−((S)−2−(ヒロドキシメチル)ピロリジン−1−イル)プロプ−1−イン−1−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−2−メチル−2−(メチルスルホニル)ブタンアミド;
18)N−ヒドロキシ−4−(4−(4−(5−ヒドロキシペンタ−1−イン−1−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−2−メチル−2−(メチルスルホニル)ブタンアミド;
19)5−(4−(1−(4−(ヒドロキシアミノ)−3−メチル−3−(メチルスルホニル)−4−オキソブチル)−1,2,3,6−テトラヒドロピリジン−4−イル)フェニル)ペンタ−4−イン−1−イルメタンスルホン酸;
20)4−(4−(4−(5−(ジメチルアミノ)ペンタ−1−イン−1−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;
21)4−(4−(4−(5−アミノペンタ−1−イン−1−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;
22)N−ヒドロキシ−4−(4−(4−(3−ヒドロキシプロプ−1−イン−1−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−2−メチル−2−(メチルスルホニル)ブタンアミド;
23)N−ヒドロキシ−4−(4−(4−(3−メトキシプロプ−1−イン−1−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−2−メチル−2−(メチルスルホニル)ブタンアミド;
24)N−ヒドロキシ−4−(4−(4−(3−(3−ヒドロキシプロポキシ)プロプ−1−イン−1−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−2−メチル−2−(メチルスルホニル)ブタンアミド;
25)N−ヒドロキシ−2−メチル−2−(メチルスルホニル)−4−(4−(4−(3−モルホリノプロプ−1−イン−1−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)ブタンアミド;
26)3−(4−(1−(4−(ヒドロキシアミノ)−3−メチル−3−(メチルスルホニル)−4−オキソブチル)−1,2,3,6−テトラヒドロピリジン−4−イル)フェニル)プロプ−2−イン−1−イルカルバミン酸;
27)5−(4−(1−(4−(ヒドロキシアミノ)−3−メチル−3−(メチルスルホニル)−4−オキソブチル)−1,2,3,6−テトラヒドロピリジン−4−イル)フェニル)ペンタ−4−イン−1−イルカルバミン酸;
28)N−ヒドロキシ−4−(4−(4−(5−メトキシペンタ−1−イン−1−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−2−メチル−2−(メチルスルホニル)ブタンアミド;
29)N−ヒドロキシ−4−(4−(4−(6−ヒドロキシヘキサ−1−イン−1−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−2−メチル−2−(メチルスルホニル)ブタンアミド;
30)N−ヒドロキシ−2−メチル−2−(メチルスルホニル)−4−(4−(4−(6−モルホリノヘキサ−1−イン−1−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)ブタンアミド;
31)4−(4−(4−(3−(ジメチルアミノ)プロプ−1−イン−1−イル)−3−フルオロフェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;
32)4−(4−(4−(3−(ジメチルアミノ)プロプ−1−イン−1−イル)−3,5−ジフルオロフェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;
33)4−(4−(4−(3−(ジメチルアミノ)プロプ−1−イン−1−イル)−2−フルオロフェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;
34)N−ヒドロキシ−2−メチル−2−(メチルスルホニル)−4−(4−(4−(チオフェン−2−イルエチニル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)ブタンアミド;
35)N−ヒドロキシ−2−メチル−2−(メチルスルホニル)−4−(4−(4−((4−ニトロフェニル)エチニル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)ブタンアミド;
36)N−ヒドロキシ−2−メチル−2−(メチルスルホニル)−4−(4−(4−(ピリジン−3−イルエチニル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イ
ル)ブタンアミド;
37)N−ヒドロキシ−4−(4−(4−((4−ヒドロキシフェニル)エチニル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−2−メチル−2−(メチルスルホニル)ブタンアミド;
38)N−ヒドロキシ−2−メチル−4−(4−(4−((1−メチル−1H−イミダゾール−4−イル)エチニル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−2−(メチルスルホニル)ブタンアミド;
39)N−ヒドロキシ−2−メチル−4−(4−(4−((1−メチルアゼチジン−3−イル)エチニル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−2−(メチルスルホニル)ブタンアミド;
40)4−(4−(4−((1−アセチルアゼチジン−3−イル)エチニル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;
41)N−ヒドロキシ−2−メチル−2−(メチルスルホニル)−4−(4−(4−((1−(メチルスルホニル)アゼチジン−3−イル)エチニル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)ブタンアミド;
42)4−(4−(3−フルオロ−4−(7−ヒドロキシヘプタ−1,3−ジイン−1−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;
43)4−(4−(3−フルオロ−4−(6−ヒドロキシヘキサ−1,3−ジイン−1−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;
44)4−(4−(4−(シクロプロピルブタ−1,3−ジイン−1−イル)−3−フルオロフェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;
45)4−(4−(4−(5−(ジメチルアミノ)ペンタ−1,3−ジイン−1−イル)−3−フルオロフェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;
46)N−ヒドロキシ−4−(4−(4−(7−ヒドロキシヘプタ−1,3−ジイン−1−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−2−メチル−2−(メチルスルホニル)ブタンアミド;
47)N−ヒドロキシ−4−(4−(4−(6−ヒドロキシヘキサ−1,3−ジイン−1−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−2−メチル−2−(メチルスルホニル)ブタンアミド;
48)N−ヒドロキシ−4−(4−(4−(5−ヒドロキシペンタ−1,3−ジイン−1−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−2−メチル−2−(メチルスルホニル)ブタンアミド;
49)4−(4−(4−(5−(ジメチルアミノ)ペンタ−1,3−ジイン−1−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;
50)N−ヒドロキシ−4−(4−(4−(5−メトキシペンタ−1,3−ジイン−1−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−2−メチル−2−(メチルスルホニル)ブタンアミド;
51)N−ヒドロキシ−2−メチル−2−(メチルスルホニル)−4−(4−(4−(フェニルブタ−1,3−ジイン−1−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)ブタンアミド;
52)N−ヒドロキシ−2−メチル−2−(メチルスルホニル)−4−(4−(ピリジン−4−イルエチニル)−3,6−ジヒドロピリジン−1(2H)−イル)ブタンアミド;
53)4−(4−((4−ブロモフェニル)エチニル)−3,6−ジヒドロピリジン−
1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;
54)N−ヒドロキシ−4−(4−(7−ヒドロキシヘプタ−1,3−ジイン−1−イル)−3,6−ジヒドロピリジン−1(2H)−イル)−2−メチル−2−(メチルスルホニル)ブタンアミド;
55)N−ヒドロキシ−2−メチル−2−(メチルスルホニル)−4−(4−(4−(ピリジン−4−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)ブタンアミド;
56)4−(4−([1,1’−ビフェニル]−4−イル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;
57)4−(4−(4’−クロロ−[1,1’−ビフェニル]−4−イル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;
58)4−(4−(4’−フルオロ−[1,1’−ビフェニル]−4−イル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;
59)N−ヒドロキシ−4−(4−(4’−ヒドロキシ−[1,1’−ビフェニル]−4−イル)−3,6−ジヒドロピリジン−1(2H)−イル)−2−メチル−2−(メチルスルホニル)ブタンアミド;
60)4−(4−(3’−フルオロ−4’−メトキシ−[1,1’−ビフェニル]−4−イル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;
61)N−ヒドロキシ−2−メチル−2−(メチルスルホニル)−4−(4−(4−(ピリジン−3−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)ブタンアミド;
62)4−(4−(4−(6−フルオロピリジン−3−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;
63)4−(4−(4−(フラン−3−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;
64)N−ヒドロキシ−2−メチル−2−(メチルスルホニル)−4−(4−(4’−(メチルスルホニル)−[1,1’−ビフェニル]−4−イル)−3,6−ジヒドロピリジン−1(2H)−イル)ブタンアミド;
65)N−ヒドロキシ−4−(4−(4’−(ヒロドキシメチル)−[1,1’−ビフェニル]−4−イル)−3,6−ジヒドロピリジン−1(2H)−イル)−2−メチル−2−(メチルスルホニル)ブタンアミド;
66)4−(4−(4’−シアノ−[1,1’−ビフェニル]−4−イル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;
67)N−ヒドロキシ−2−メチル−2−(メチルスルホニル)−4−(4−(4’−ペンチル−[1,1’−ビフェニル]−4−イル)−3,6−ジヒドロピリジン−1(2H)−イル)ブタンアミド;
68)4−(4−(4’−(アゼチジン−1−イルスルホニル)−[1,1’−ビフェニル]−4−イル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;
69)4’−(1−(4−(ヒドロキシアミノ)−3−メチル−3−(メチルスルホニル)−4−オキソブチル)−1,2,3,6−テトラヒドロピリジン−4−イル)−[1,1’−ビフェニル]−4−イルメタンスルホン酸;
70)N−ヒドロキシ−2−メチル−2−(メチルスルホニル)−4−(4−(4−(チオフェン−3−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)ブタンアミド;
71)N−ヒドロキシ−4−(4−(4−(3−メトキシチオフェン−2−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−2−メチル−2−(メチルスルホニル)ブタンアミド;
72)N−ヒドロキシ−2−メチル−2−(メチルスルホニル)−4−(4−(4−(4−メチルチオフェン−2−イル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)ブタンアミド;
73)4−(4−(4’−(エチルスルホニル)−[1,1’−ビフェニル]−4−イル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;
74)N−ヒドロキシ−2−メチル−2−(メチルスルホニル)−4−(4−(4’−(モルホリノメチル)−[1,1’−ビフェニル]−4−イル)−3,6−ジヒドロピリジン−1(2H)−イル)ブタンアミド;
75)N−ヒドロキシ−4−(6−(3−メトキシプロプ−1−イン−1−イル)−3’,6’−ジヒドロ−[3,4’−ビピリジン]−1’(2’H)−イル)−2−メチル−2−(メチルスルホニル)ブタンアミド;
76)3−(4−([1,1’−ビフェニル]−4−イル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)プロパンアミド;
77)4−(4−(4−(3−(ジメチルアミノ)プロプ−1−イン−1−イル)−3−メチルフェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド;および
78)4−(4−(4−(3−(ジメチルアミノ)プロプ−1−イン−1−イル)−3−(トリフルオロメチル)フェニル)−3,6−ジヒドロピリジン−1(2H)−イル)−N−ヒドロキシ−2−メチル−2−(メチルスルホニル)ブタンアミド。 - UDP−3−O−(R−3−ヒドロキシミリストイル)−N−アセチルグルコサミンデアセチラーゼ(LpxC)を阻害するための医薬組成物であって、請求項1〜3のいずれか一項に記載の化合物、その立体異性体またはその薬剤的に許容できる塩を含む、医薬組成物。
- 細菌感染症を治療するための医薬組成物であって、請求項1〜3のいずれか一項に記載の化合物、その立体異性体またはその薬剤的に許容できる塩を含む、医薬組成物。
- 前記細菌感染症がグラム陰性菌によって引き起こされる、請求項5に記載の医薬組成物。
- 前記細菌感染症が院内肺炎、尿路感染症、全身感染症、皮膚軟組織感染症、外科感染症、腹腔内感染症、肺感染症、心内膜炎、糖尿病性足感染症、骨髄炎、および中枢神経系感染症からなる群から選択される、請求項6に記載の医薬組成物。
- 細菌感染症を治療するための医薬の調製における、請求項1〜3のいずれか一項に記載の化合物、その立体異性体またはその薬剤的に許容できる塩の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662400694P | 2016-09-28 | 2016-09-28 | |
US62/400,694 | 2016-09-28 | ||
PCT/KR2017/010896 WO2018062924A1 (en) | 2016-09-28 | 2017-09-28 | Tetrahydropyridine derivatives and their use as antibacterial agents |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019534252A JP2019534252A (ja) | 2019-11-28 |
JP6812542B2 true JP6812542B2 (ja) | 2021-01-13 |
Family
ID=61687790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019516938A Active JP6812542B2 (ja) | 2016-09-28 | 2017-09-28 | テトラヒドロピリジン誘導体および抗菌剤としてのその使用 |
Country Status (15)
Country | Link |
---|---|
US (1) | US10160724B2 (ja) |
EP (1) | EP3519387B1 (ja) |
JP (1) | JP6812542B2 (ja) |
KR (1) | KR102264248B1 (ja) |
CN (1) | CN110088087B (ja) |
AU (1) | AU2017337946B2 (ja) |
BR (1) | BR112019006129A2 (ja) |
CA (1) | CA3037118C (ja) |
ES (1) | ES2891025T3 (ja) |
MX (1) | MX2019003585A (ja) |
PL (1) | PL3519387T3 (ja) |
PT (1) | PT3519387T (ja) |
RU (1) | RU2722594C1 (ja) |
WO (1) | WO2018062924A1 (ja) |
ZA (1) | ZA201901945B (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL277071B1 (en) | 2018-03-08 | 2024-03-01 | Incyte Corp | Aminopyrizine diol compounds as PI3K–y inhibitors |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0311201D0 (en) * | 2003-05-15 | 2003-06-18 | Merck Sharp & Dohme | Therapeutic agents |
WO2009008905A1 (en) * | 2007-02-01 | 2009-01-15 | Panthera Biopharma, Llc. | Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning |
EP2488489A2 (en) * | 2009-10-13 | 2012-08-22 | Pfizer Inc. | C-linked hydroxamic acid derivatives useful as antibacterial agents |
CA2830866A1 (en) * | 2011-04-08 | 2012-10-11 | Pfizer Inc. | Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents |
CA2830920C (en) * | 2011-04-08 | 2015-07-14 | Pfizer Inc. | Isoxazole derivatives useful as antibacterial agents |
WO2013170165A1 (en) | 2012-05-10 | 2013-11-14 | Achaogen, Inc. | Antibacterial agents |
JP6514716B2 (ja) * | 2014-04-22 | 2019-05-15 | ノバルティス アーゲー | LpxC阻害剤としてのイソオキサゾリンヒドロキサム酸誘導体 |
CA2948077A1 (en) * | 2014-05-16 | 2015-11-19 | Actelion Pharmaceuticals Ltd | Antibacterial quinazoline-4(3h)-one derivatives |
CA3007653A1 (en) * | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Substituted benzazinones as antibacterial compounds |
-
2017
- 2017-09-28 CA CA3037118A patent/CA3037118C/en active Active
- 2017-09-28 BR BR112019006129A patent/BR112019006129A2/pt active Search and Examination
- 2017-09-28 RU RU2019112881A patent/RU2722594C1/ru active
- 2017-09-28 AU AU2017337946A patent/AU2017337946B2/en active Active
- 2017-09-28 EP EP17856810.1A patent/EP3519387B1/en active Active
- 2017-09-28 PL PL17856810T patent/PL3519387T3/pl unknown
- 2017-09-28 JP JP2019516938A patent/JP6812542B2/ja active Active
- 2017-09-28 WO PCT/KR2017/010896 patent/WO2018062924A1/en unknown
- 2017-09-28 ES ES17856810T patent/ES2891025T3/es active Active
- 2017-09-28 CN CN201780059711.8A patent/CN110088087B/zh active Active
- 2017-09-28 MX MX2019003585A patent/MX2019003585A/es unknown
- 2017-09-28 PT PT178568101T patent/PT3519387T/pt unknown
- 2017-09-28 US US15/718,474 patent/US10160724B2/en active Active
- 2017-09-28 KR KR1020197012063A patent/KR102264248B1/ko active IP Right Grant
-
2019
- 2019-03-28 ZA ZA2019/01945A patent/ZA201901945B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3519387B1 (en) | 2021-08-11 |
KR102264248B1 (ko) | 2021-06-14 |
BR112019006129A2 (pt) | 2019-06-18 |
ZA201901945B (en) | 2022-07-27 |
US10160724B2 (en) | 2018-12-25 |
EP3519387A4 (en) | 2020-05-13 |
JP2019534252A (ja) | 2019-11-28 |
AU2017337946A1 (en) | 2019-04-04 |
US20180086709A1 (en) | 2018-03-29 |
NZ751511A (en) | 2020-11-27 |
PT3519387T (pt) | 2021-09-28 |
MX2019003585A (es) | 2019-06-10 |
PL3519387T3 (pl) | 2022-02-07 |
CN110088087B (zh) | 2022-08-09 |
CN110088087A (zh) | 2019-08-02 |
CA3037118C (en) | 2021-12-14 |
CA3037118A1 (en) | 2018-04-05 |
EP3519387A1 (en) | 2019-08-07 |
RU2722594C1 (ru) | 2020-06-02 |
KR20190047127A (ko) | 2019-05-07 |
ES2891025T3 (es) | 2022-01-25 |
WO2018062924A1 (en) | 2018-04-05 |
AU2017337946B2 (en) | 2020-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5227304B2 (ja) | 新規なヒドロキサム酸誘導体 | |
AU2012238374B2 (en) | Isoxazole derivatives useful as antibacterial agents | |
AU2016275764B2 (en) | Efflux-pump inhibitors and therapeutic uses thereof | |
WO2014160649A1 (en) | Hydroxamic acid derivatives as lpxc inhibitors for the treatment of bacterial infections | |
KR20130131459A (ko) | 항균제로서 유용한 플루오로-피리디논 유도체 | |
CN112074507B (zh) | 作为抗菌素的化合物 | |
JP6514716B2 (ja) | LpxC阻害剤としてのイソオキサゾリンヒドロキサム酸誘導体 | |
JP6812542B2 (ja) | テトラヒドロピリジン誘導体および抗菌剤としてのその使用 | |
CN107001300A (zh) | 抗菌性苯并噻唑衍生物 | |
CA3022102A1 (en) | Benzoylglycine derivatives and methods of making and using same | |
JP2024507140A (ja) | 抗菌性化合物 | |
NZ751511B2 (en) | Tetrahydropyridine derivatives and their use as antibacterial agents | |
RU2795119C2 (ru) | Соединение, обладающее циклической структурой | |
EP4347607A1 (en) | Penicillin-binding protein inhibitors | |
CN117693511A (zh) | 青霉素结合蛋白抑制剂 | |
TW202120508A (zh) | 廣效碳青黴烯類 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190528 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190528 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200227 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200303 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200602 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200924 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200924 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201124 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201216 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6812542 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |